As you will be aware The Department for Health & Social Care has asked NICE to conduct an appraisal of Mepolizumab for treating chronic obstructive pulmonary disease with eosinophilic bronchitis [ID1237].
Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early July 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early September 2025.